BioCentury | Oct 5, 2015

Drawn and quartered

There was no joy to be had in 3Q15, as every biotech market cap band fell by at least 15%. After the carnage only one group - companies valued north of $5 billion - are in the...
BC Week In Review | Aug 3, 2015
Clinical News

Bioabsorbable Cardiac Matrix: Phase II data

Top-line data from the double-blind, international Phase II PRESERVATION I trial in 303 patients who had successful percutaneous coronary intervention (PCI) following acute ST-segment elevation myocardial infarction (STEMI) showed that 4 mL intracoronary BCM missed...
BC Extra | Jul 28, 2015
Clinical News

Bellerophon plummets on BCM data

Bellerophon Therapeutics Inc. (NASDAQ:BLPH) lost $4.26 (56%) to $3.39 on Monday, bringing its market cap to $43.7 million, after the PRESERVATION I trial of its Bioabsorbable Cardiac Matrix (BCM) device ( BL-1040 ) missed its primary endpoint....
BioCentury | Mar 23, 2015
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/20 cls Actelion Ltd. (SIX:ATLN) UBS Guillaume van Renterghem Downgrade Neutral (from buy) 4% CHF 118.90 van Renterghem downgraded after...
BC Extra | Feb 14, 2015
Financial News

Bellerophon falls after $60M IPO

Bellerophon Therapeutics LLC (NASDAQ:BLPH) lost $3.03 (25%) to $8.97 in its first day of trading Friday after raising $60 million in an IPO on NASDAQ through the sale of 5 million shares at $12. The...
BC Extra | Mar 5, 2014
Financial News

BioLineRx raises $21 million

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) raised $21 million through the sale of 8.4 million ADSs at $2.50 in a follow-on underwritten by Roth Capital Partners and Maxim Group. Each ADS represents 10 common shares. BioLineRx...
BC Week In Review | Jan 6, 2014
Company News

Ikaria, Madison Dearborn Partners deal

On Dec. 24, 2013, private equity firm Madison Dearborn said it will acquire the majority stake in the commercial business of Ikaria in a deal the parties said values the business at about $1.6 billion....
BC Extra | Dec 27, 2013
Company News

PE firm acquiring majority stake of Ikaria's commercial business

Private equity firm Madison Dearborn Partners will acquire the majority stake in the commercial business of Ikaria Inc. (Hampton, N.J.) in a deal the parties said values the business at about $1.6 billion. Existing Ikaria...
BC Week In Review | Mar 25, 2013
Clinical News

BL-1020: Phase II/III discontinued

BioLineRx discontinued the double-blind, international Phase II/III CLARITY trial after a pre-planned interim analysis of 168 evaluable patients experiencing an acute exacerbation of schizophrenia showed that oral BL-1020 would not meet the primary endpoint of...
BC Extra | Mar 21, 2013
Clinical News

BioLineRx plummets after discontinuing CLARITY trial

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) fell $2.01 (53%) to $1.80 on Wednesday after discontinuing the Phase II/III CLARITY trial evaluating BL-1020 to treat schizophrenia. The move came after a pre-planned interim analysis of 168 evaluable...
Items per page:
1 - 10 of 22